<b>Methods:</b> A retrospective analysis was conducted on 95 patients with DLBCL meeting DE criteria by immunohistochemistry (MYC protein expression ≥ 40% , BCL-2 protein expression ≥ 50% ) treated at the First Affiliated Hospital of Nanjing Medical University between June 2021 and June 2024. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.